

5.1.2e

EMEA Vaccine Alliance Lead & Janssen The Netherlands Campus Lead

Janssen Vaccines and Prevention B.V.

Archimedesweg 4-6, 2333 CN Leiden, The Netherlands PO Box 2048, 2301 CA Leiden, The Netherlands

Mobile: +31 (0)6 5.1.2e

Phone office: +31 (0)71 5.1.2e

5.1.2e @its.jnj.com

Confidentiality Notice: This e-mail transmission is confidential and may be privileged information that is intended only for the individual or entity named in the e-mail address. If you are not the intended recipient and believe you have received this e-mail transmission in error, please reply to the sender, so that we can arrange for proper delivery, and then please delete the message from your inbox. The unauthorized use, dissemination, distribution or reproduction of this e-mail, including attachments, is prohibited and may be unlawful. Receipt by anyone other than the intended recipient(s) is not a waiver of any attorney/client or other privilege. Thank you.

-----Original Message-----

From: 5.1.2e <5.1.2e@minvws.nl>

Sent: zaterdag 30 januari 2021 17:51

To: 5.1.2e [JRDNL] <5.1.2e@its.jnj.com>

Cc: 5.1.2e | 5.1.2e <5.1.2e@ITS.JNJ.com>; 5.1.2e [JRDNL] <5.1.2e@its.jnj.com>; 5.1.2e | 5.1.2e

<5.1.2e@its.jnj.com>

Subject: [EXTERNAL] RE: J&J Announces Topline Phase 3 Data for COVID-19 Vaccine

5.1.2e

Ik snap jullie zorgen.

Het gaat hier niet per se om een exportverbod. Maar door alle politieke ophef de afgelopen week, was een reactie noodzakelijk.

Het gaat allereerst om transparantie. Het moet duidelijk zijn dat er geen vaccins de EU verlaten, die voor de EU bedoeld waren.

Alleen het feit dat daar vragen over bestaan, maakt dat dit instrument noodzakelijk is.

Weet verder dat de 5.1.2a en het 5.1.2a ook al gebruik maken van vergelijkbare instrumenten.

Maar nogmaals jullie zorgen snappen we. Het instrument is vooralsnog ook een tijdelijke maatregel.

Bel me volgende week gerust als je vragen hebt.

Groet,

5.1.2e

Verzonden met BlackBerry Work

www.blackberry.com

Van: 5.1.2e | 5.1.2e <5.1.2e@its.jnj.com> <5.1.2e@its.jnj.com>>

Datum: vrijdag 29 jan. 2021 8:33 PM

Aan: 5.1.2e <5.1.2e@minvws.nl> <5.1.2e@minvws.nl>>

Kopie: 5.1.2e | 5.1.2e <5.1.2e@ITS.JNJ.com> <5.1.2e@ITS.JNJ.com>>, 5.1.2e | 5.1.2e

<5.1.2e@its.jnj.com> <5.1.2e@its.jnj.com>>, 5.1.2e | 5.1.2e <5.1.2e@its.jnj.com> <5.1.2e@its.jnj.com>>

Onderwerp: RE: J&J Announces Topline Phase 3 Data for COVID-19 Vaccine

Beste 5.1.2e

Hartelijk dank voor je mail.

Mbt je vraag in zake een regimen met 2 doses: onze grote fase 3 trial met een 2 dose regimen is in November 2020 gestart; we verwachten de eerste resultaten in de tweede helft van dit jaar.

Hoewel het weekend net is begonnen, vind ik het toch belangrijk om je te laten weten dat we ons zorgen maken over de laatste ontwikkelingen in het geschil tussen de Commissie en AstraZeneca. De details ken ik niet en daar wil ik mij ook niet over uitlaten maar de stap van de Commissie om export notificaties en vergunningen in te voeren voor alle vaccins leidt tot veel onzekerheid en zorgen binnen J&J. We zijn bang dat dit kan gaan

leiden tot (tegen)reacties van andere landen en daardoor de in/export van vaccins, halffabrikaten en grondstoffen gaat verstoren. Dat zou ons eigen wereldwijde netwerk voor productie van het vaccin met daarin een sleutelrol van Leiden, ernstig kunnen verstoren. We hebben deze zorg vandaag al gedeeld via de [REDACTED] [REDACTED]. Is het mogelijk om daar dit weekend nog met jou even over te spreken?

Met vriendelijke groeten, [REDACTED]

Kind regards / Met vriendelijke groet

[REDACTED]
EMEA Vaccine Alliance Lead & Janssen The Netherlands Campus Lead | [REDACTED]@[REDACTED]

Janssen Vaccines and Prevention B.V.
Archimedesweg 4-6, 2333 CN Leiden, The Netherlands PO Box 2048, 2301 CA Leiden, The Netherlands
Mobile: +31 (0)6 1 [REDACTED]
Phone office: +31 (0)71 [REDACTED]
[REDACTED]@its.jnj.com <[REDACTED]@its.jnj.com>

Confidentiality Notice: This e-mail transmission is confidential and may be privileged information that is intended only for the individual or entity named in the e-mail address. If you are not the intended recipient and believe you have received this e-mail transmission in error, please reply to the sender, so that we can arrange for proper delivery, and then please delete the message from your inbox. The unauthorized use, dissemination, distribution or reproduction of this e-mail, including attachments, is prohibited and may be unlawful. Receipt by anyone other than the intended recipient(s) is not a waiver of any attorney/client or other privilege. Thank you.

From: [REDACTED] <[REDACTED]@minvws.nl>
Sent: vrijdag 29 januari 2021 17:24
To: [REDACTED] [REDACTED] <[REDACTED]@its.jnj.com>
Cc: [REDACTED] [REDACTED] <[REDACTED]@ITS.JNJ.com>
Subject: [EXTERNAL] RE: J&J Announces Topline Phase 3 Data for COVID-19 Vaccine

WARNING: This email originated from outside the company. Do not click on links unless you recognize the sender and have confidence the content is safe. If you have concerns about this email, send it as an attachment to [REDACTED]@[REDACTED]; [REDACTED]@ITS.JNJ.COM>.

Ik zag het. Gefeliciteerd.

Verwacht je nog dat jullie ook nog gaan nadenken over twee doses?

Groet,

[REDACTED]

Van: [REDACTED] [REDACTED] [JRDNL] <[REDACTED]@its.jnj.com> <[REDACTED]@its.jnj.com>>
Verzonden: vrijdag 29 januari 2021 17:01
Aan: [REDACTED] <[REDACTED]@minvws.nl> <[REDACTED]@minvws.nl>>
CC: [REDACTED] [REDACTED] <[REDACTED]@ITS.JNJ.com> <[REDACTED]@ITS.JNJ.com>>; [REDACTED] [REDACTED] <[REDACTED]@its.jnj.com> <[REDACTED]@its.jnj.com>>
Onderwerp: J&J Announces Topline Phase 3 Data for COVID-19 Vaccine

[Picture 1]

[A picture containing drawing, light Description automatically generated]

Dear [REDACTED]

Today marks a major milestone in Johnson & Johnson's efforts to develop a COVID-19 vaccine. I am delighted to share the enclosed communication from [REDACTED] [REDACTED] Johnson & Johnson.

In the enclosed, [REDACTED] summarizes key points about the first interim Phase 3 clinical trial data for the Janssen COVID-19 vaccine candidate, as well as highlighting other key progress that we are making as we gear up to make the vaccine available globally.

For your reference I am also including the Press Release that was issued earlier today.

Please let me know if you have any questions about [REDACTED] 5.1.2e update - I'd be happy to answer any questions you may have. Looking forward to our discussions next week.

Sincerely,

[REDACTED] 5.1.2e

[REDACTED] 5.1.2e

EMEA Vaccine Alliance Lead & Janssen The Netherlands Campus Lead

[REDACTED] 5.1.2e @ [REDACTED] 5.1.2e

Janssen Vaccines and Prevention B.V.

Archimedesweg 4-6, 2333 CN Leiden, The Netherlands PO Box 2048, 2301 CA Leiden, The Netherlands

Mobile: +31 (0)6 [REDACTED] 5.1.2e

Phone office: +31 (0)71 [REDACTED] 5.1.2e

[REDACTED] 5.1.2e @its.jnj.com <[REDACTED] 5.1.2e @its.jnj.com>

Confidentiality Notice: This e-mail transmission is confidential and may be privileged information that is intended only for the individual or entity named in the e-mail address. If you are not the intended recipient and believe you have received this e-mail transmission in error, please reply to the sender, so that we can arrange for proper delivery, and then please delete the message from your inbox. The unauthorized use, dissemination, distribution or reproduction of this e-mail, including attachments, is prohibited and may be unlawful. Receipt by anyone other than the intended recipient(s) is not a waiver of any attorney/client or other privilege. Thank you.